Translocation of AIF in the human and rat striatum following protracted haloperidol, but not clozapine treatment

Apoptosis

Volumn 11, Issue 5, 2006, Pages 663-672

  Skoblenick, K J ^a   Castellano, J M ^a   Rogoza, R M ^a   Dyck, B A ^a   Thomas, N ^a   Gabriele, J P ^a   Chong, V Z ^a   Mishra, R K ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Apoptosis inducing factor; Clozapine; Haloperidol; Schizophrenia; Tardive dyskinesia

Indexed keywords

APOPTOSIS INDUCING FACTOR; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CORPUS STRIATUM; GENE TRANSLOCATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; TARDIVE DYSKINESIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; APOPTOSIS; APOPTOSIS INDUCING FACTOR; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CELL NUCLEUS; CELL SURVIVAL; CLOZAPINE; CORPUS STRIATUM; HALOPERIDOL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MITOCHONDRIA; NEUROBLASTOMA; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33745030386     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-006-5698-6     Document Type: Article

References (52)

1. Correll CU, Malhotra AK. Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology (Berl) 2004; 174: 477-489.
2. Kapur S, Seeman P. Transient Occupancy at the D2 Receptor-A new hypothesis for atypical antipsychotics. Biol Psychiatry 2000; 47: 695.
3. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999; 156: 286-293.
4. Masellis M, Basile VS, Ozdemir V, Meltzer HY, Macciardi FM, Kennedy JL. Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine. Biol Psychiatry 2000; 47: 252-266.
5. Roth BL, Meltzer HY, Khan N. Binding of typical and atypical antipsychotic drugs to multiple neurotransmitter receptors. Adv Pharmacol 1998; 42: 482-485.
6. Seeman P. Atypical antipsychotics: Mechanism of action. Can J Psychiatry 2002; 47: 27-38.
7. Singh AN, Barlas C, Saeedi H, Mishra RK. Effect of loxapine on peripheral dopaminelike and serotonin receptors in patients with schizophrenia. J Psychiatry Neurosci 2003; 28: 39-47.
8. Tauscher J, Hussain T, Agid O, et al. Equivalent occupancy of dopamme d1 and d2 receptors with clozapine: differentiation from other atypical antipsychotics. Am J Psychiatry 2004; 161: 1620-1625.
9. Costain WJ, Gupta SK, Johnson RL, Mishra RK. Modulation of G proteins in rat striatum by neuroleptic drugs and a peptidomimetic analogue of PLG. In: Role of G Proteins in Neurological and Psychiatry Disorders. Eds. R.K. Mishra, G.Baker, and A. Boulton. pp 119-138. New Jersey: Humana Press 1998: 119-138.
10. Gupta SK, Mishra RK. Effects of chronic treatment of haloperidol and clozapine on levels of Gprotein subunits in rat striatum. J Mol Neurosci 1992; 3: 197-201.
11. MacGibbon GA, Lawlor PA, Bravo R, Dragunow M. Clozapine and haloperidol produce a differential pattern of immediate early gene expression in rat caudateputamen, nucleus accumbens, lateral septum and islands of Calleja. Brain Res Mol Brain Res 1994; 23: 21-32.
12. Simpson GM. The treatment of tardive dyskinesia and tardive dystonia. J Clin Psychiatry 2000; 61(Suppl 4): 39-44.
13. Glazer WM. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry 2000; 61(Suppl 3): 16-21.
14. Grunder G, Carlsson A, Wong DF. Mechanism of new antipsychotic medications: Occupancy is not just antagonism. Arch Gen Psychiatry 2003; 60: 974-977.
15. Tauscher J, Hussain T, Agid O, et al. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. Am J Psychiatry 2004; 161: 1620-1625.
16. Chong VZ, Young LT, Mishra RK. cDNA array reveals differential gene expression following chronic neuroleptic administration: implications of synapsin II in haloperidol treatment. J Neurochem 2002; 82: 1533-1539.
17. Hoff JI, van Hilten BJ, Roos RA. A review of the assessment of dyskinesias. Mov Disord 1999; 14: 737-743.
18. Latimer PR. Tardive dyskinesia: A review. Can J Psychiatry 1995; 40: S49S54.
19. Kane JM. Extrapyramidal side effects are unacceptable. Eur Neuropsychopharmacol 2001; 11(Suppl 4): S397-S403.
20. Soares KV, McGrath JJ. The treatment of tardive dyskinesiaa systematic review and metaanalysis. Schizophr Res 1999; 39: 1-16.
21. Rogoza RM, Fairfax DF, Henry P, et al. Electron spin resonance spectroscopy reveals alphaphenylN tertbutylnitrone spintraps free radicals in rat striatum and prevents haloperidolinduced vacuous chewing movements in the rat model of human tardive dyskinesia. Synapse 2004; 54: 156.
22. Cao G, Clark RS, Pei W, et al. Translocation of apoptosisinducing factor in vulnerable neurons after transient cerebral ischemia and in neuronal cultures after oxygenglucose deprivation. J Cereb Blood Flow Metab 2003; 23: 1137-1150.
23. Susin SA, Lorenzo HK, Zamzami N, et al. Molecular characterization of mitochondrial apoptosisinducing factor. Nature 1999; 397: 441-446.
24. Cande C, Cecconi F, Dessen P, Kroemer G. Apoptosisinducing factor (AIF): Key to the conserved caspaseindependent pathways of cell death?. J Cell Sci 2002; 115: 4727-4734.
25. Cande C, Cohen I, Daugas E, et al. Apoptosisinducing factor (AIF): a novel caspaseindependent death effector released from mitochondria. Biochimie 2002; 84: 215-222.
26. Cregan SP, Fortin A, MacLaurin JG, et al. Apoptosisinducing factor is involved in the regulation of caspaseindependent neuronal cell death. J Cell Biol 2002; 158: 507-517.
27. Susin SA, Daugas E, Ravagnan L, et al. Two distinct pathways leading to nuclear apoptosis. J Exp Med 2000; 192: 571-580.
28. Wang X, Yang C, Chai J, Shi Y, Xue D. Mechanisms of AIF-mediated apoptotic DNA degradation in Caenorhabditis elegans. Science 2002; 298: 1587-1592.
29. Yu SW, Wang H, Poitras MF, et al. Mediation of poly(ADPribose) polymerase1 dependent cell death by apoptosisinducing factor. Science 2002; 297: 259-263.
30. Kapur S, VanderSpek SC, Brownlee BA, Nobrega JN. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: A suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 2003; 305: 625-631.
31. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus lowpotency conventional antipsychotics: A systematic review and metaanalysis. Lancet 2003; 361: 1581-1589.
32. Costain WJ, Mishra RK. PLG regulates hnRNPL expression in the rat striatum and prefrontal cortex: Identification by ddPCR. Peptides 2003; 24: 137-146.
33. Jope RS, Song L. AP1 and NFkappaB stimulated by carbachol in human neuroblastoma SH SY5Y cells are differentially sensitive to inhibition by lithium. Brain Res Mol Brain Res 1997; 50: 171-180.
34. Nair VD, Niznik HB, Mishra RK. Interaction of NMDA and dopamine D2L receptors in human neuroblastoma SHSY5Y cells. J Neurochem 1996; 66: 2390-2393.
35. Nair VD, Mishra RK. Molecular cloning, localization and characterization of a 40kDa catecholamineregulated protein. J Neurochem 2001; 76: 1142-1152.
36. Sharan N, Nair VD, Mishra RK. Modulation of a 40-kDa catecholamine regulated protein by dopamine receptor antagonists. Eur J Pharmacol 2001; 413: 73-79.
37. Chong VZ, Costain W, Marriott J, et al. Differential display polymerase chain reaction reveals increased expression of striatal rat gliaderived nexin following chronic clozapine treatment. Pharmacogenomics J 2004; 4: 379-387.
38. Goto A, Doering L, Nair VD, Mishra RK. Immunohistochemical localization of a 40kDa catecholamine regulated protein in the nigrostriatal pathway. Brain Res 2001; 900: 314-319.
39. Mitchell IJ, Cooper AC, Griffiths MR, Cooper AJ. Acute administration of haloperidol induces apoptosis of neurones in the striatum and substantia nigra in the rat. Neuroscience 2002; 109: 89-99.
40. Casey DE. Tardive dyskinesia: pathophysiology and animal models. J Clin Psychiatry 2000; 61(Suppl 4): 5-9.
41. Qing H, Xu H, Wei Z, Gibson K, Li XM. The ability of atypical antipsychotic drugs vs. haloperidol to protect PC12 cells against MPP induced apoptosis. Eur J Neurosci 2003; 17: 1563-1570.
42. Tsai G, Goff DC, Chang RW, Flood J, Baer L, Coyle JT. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry 1998; 155: 1207-1213.
43. Floyd RA. Role of oxygen free radicals in carcinogenesis and brain ischemia. FASEB J 1990; 4: 2587-2597.
44. Ukai W, Ozawa H, Tateno M, Hashimoto E, Saito T. Neurotoxic potential of haloperidol in comparison with risperidone: Implication of Aktmediated signal changes by haloperidol. J Neural Transm 2004; 111: 667-681.
45. Daugas E, Susin SA, Zamzami N, et al. Mitochondrio-nuclear translocation of AIF in apoptosis and necrosis. FASEB J 2000; 14: 729-739.
46. Jayanthi S, Deng X, Noailles PA, Ladenheim B, Cadet JL. Methamphetamine induces neuronal apoptosis via crosstalks between endoplasmic reticulum and mitochondriadependent death cascades. FASEB J 2004; 18: 238-251.
47. Zhang X, Chen J, Graham SH, et al. Intranuclear localization of apoptosisinducing factor (AIF) and large scale DNA fragmentation after traumatic brain injury in rats and in neuronal cultures exposed to peroxynitrite. J Neurochem 2002; 82: 181-191.
48. Zhu C, Qiu L, Wang X, et al. Involvement of apoptosisinducing factor in neuronal death after hypoxiaischemia in the neonatal rat brain. J Neurochem 2003; 86: 306-317.
49. Sharma S, Paladino P, Gabriele J, et al. ProLeuglycinamide and its peptidomimetic, PAOPA, attenuate haloperidol induced vacuous chewing movements in rat: A model of human tardive dyskinesia. Peptides 2003; 24: 313-319.
50. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with secondgeneration antipsychotics: A systematic review of 1year studies. Am J Psychiatry 2004; 161: 414425.
51. Seeman P, Kapur S. Schizophrenia: more dopamine, more D2 receptors. Proc Natl Acad Sci USA 2000; 97: 7673-7675.
52. Gabriele JP, Chong VZ, Pontoriero GF, Mishra RK. Decreased expression of a 40-kDa catecholamineregulated protein in the ventral striatum of schizophrenic brain specimens from the Stanley Foundation Neuropathology Consortium. Schizophr Res 2005; 74: 111-119.